Human disease
POPULARITY
Categories
137 episodes with hpv
94 episodes with hpv
25 episodes with hpv
13 episodes with hpv
17 episodes with hpv
33 episodes with hpv
16 episodes with hpv
11 episodes with hpv
9 episodes with hpv
18 episodes with hpv
17 episodes with hpv
8 episodes with hpv
13 episodes with hpv
11 episodes with hpv
13 episodes with hpv
15 episodes with hpv
6 episodes with hpv
15 episodes with hpv
16 episodes with hpv
7 episodes with hpv
9 episodes with hpv
9 episodes with hpv
10 episodes with hpv
20 episodes with hpv
5 episodes with hpv
5 episodes with hpv
9 episodes with hpv
12 episodes with hpv
3 episodes with hpv
11 episodes with hpv
4 episodes with hpv
4 episodes with hpv
6 episodes with hpv
8 episodes with hpv
9 episodes with hpv
6 episodes with hpv
6 episodes with hpv
6 episodes with hpv
7 episodes with hpv
11 episodes with hpv
4 episodes with hpv
6 episodes with hpv
5 episodes with hpv
5 episodes with hpv
4 episodes with hpv
8 episodes with hpv
3 episodes with hpv
5 episodes with hpv
10 episodes with hpv
9 episodes with hpv
11 episodes with hpv
3 episodes with hpv
3 episodes with hpv
6 episodes with hpv
9 episodes with hpv
6 episodes with hpv
6 episodes with hpv
3 episodes with hpv
3 episodes with hpv
4 episodes with hpv
5 episodes with hpv
6 episodes with hpv
6 episodes with hpv
4 episodes with hpv
6 episodes with hpv
5 episodes with hpv
4 episodes with hpv
5 episodes with hpv
3 episodes with hpv
4 episodes with hpv
5 episodes with hpv
4 episodes with hpv
5 episodes with hpv
7 episodes with hpv
3 episodes with hpv
5 episodes with hpv
3 episodes with hpv
4 episodes with hpv
11 episodes with hpv
6 episodes with hpv
2 episodes with hpv
4 episodes with hpv
4 episodes with hpv
7 episodes with hpv
4 episodes with hpv
4 episodes with hpv
2 episodes with hpv
4 episodes with hpv
4 episodes with hpv
3 episodes with hpv
2 episodes with hpv
8 episodes with hpv
2 episodes with hpv
5 episodes with hpv
4 episodes with hpv
4 episodes with hpv
2 episodes with hpv
2 episodes with hpv
4 episodes with hpv
4 episodes with hpv
3 episodes with hpv
3 episodes with hpv
3 episodes with hpv
4 episodes with hpv
4 episodes with hpv
3 episodes with hpv
7 episodes with hpv
3 episodes with hpv
2 episodes with hpv
5 episodes with hpv
5 episodes with hpv
5 episodes with hpv
2 episodes with hpv
2 episodes with hpv
5 episodes with hpv
4 episodes with hpv
6 episodes with hpv
3 episodes with hpv
4 episodes with hpv
4 episodes with hpv
3 episodes with hpv
2 episodes with hpv
5 episodes with hpv
3 episodes with hpv
3 episodes with hpv
4 episodes with hpv
4 episodes with hpv
2 episodes with hpv
8 episodes with hpv
2 episodes with hpv
3 episodes with hpv
2 episodes with hpv
3 episodes with hpv
6 episodes with hpv
6 episodes with hpv
3 episodes with hpv
4 episodes with hpv
4 episodes with hpv
4 episodes with hpv
6 episodes with hpv
3 episodes with hpv
3 episodes with hpv
2 episodes with hpv
6 episodes with hpv
Dr. Peter Sinton, MD, FAAP, joins FACTSinnated to talk adolescent vaccination, misinformation, and the questions he hears from young people and families in his rural practice. Hear his perspective on HPV and meningitis vaccines, finding trusted health information, and helping young people take an active role in their healthcare decisions.
Czy szczepienia przeciw HPV staną się w Polsce obowiązkowe od 1 stycznia 2027 roku? To pytanie od miesięcy pojawia się w debacie publicznej. Ministerstwo Zdrowia zapowiadało zmianę przepisów, ale na razie nie ma podpisanego rozporządzenia, które przesądzałoby o tej dacie. O sprawę pytany był poseł Konfederacji Grzegorz Płaczek.
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3zk —— 以上為 Firstory Podcast 廣告 —— 加入會員，支持節目： https://cl75oj0i300hk01tacthrhmsk.firstory.cc/join為什麼碰不得？「佛足石」到底是什麼？所以所有東西只要歷史文物就該用什麼樣的角度與立場去看待呢留言告訴我你對這一集的想法： https://open.firstory.fm/user/cl75oj0i300hk01tacthrhmsk/comments Powered by Firstory Hosting
“We're living at the end of an empire, and we're just going to have to get through it. And thank God A24 is here to help.”This week's scariest movie is... It Part One. This film has everything: trademarked clown faces, forehead-stabbing greaser bangs, And French hair bikinis. If you love pre-sewer inhaler bumps, ass-first spider snacks, and HPV friendship pacts, this episode's for you!Please Subscribe, Rate, and Review The Horror Virgin to help more people discover our community.What did you think of our episode on It Part One? Tell us on social media @HorrorVirgin on Facebook and Instagram, or @HorrorVirginPod on Twitter.Up Next: It Part Two (1990)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep47e —— 以上為 Firstory Podcast 廣告 —— 主持人：謝金色老師加入會員，支持節目： https://careradio.firstory.cc/join留言告訴我你對這一集的想法： https://open.firstory.me/user/ckfxksqylr84j08000h3ze64h/comments Powered by Firstory Hosting
HPV? Oled kuulnud, aga täpselt ei tea? Ma ka ei tea! Aga oma kokkupuute sellega olen saanud. Jagangi täpselt nii, nagu üks naisterahvas, kes asjast midagi ei tea, seda teemat tajub. Juhul, kui sul on HPV-ga seonduv opp ees ootamas või said just teada, et on rakumuudatused - siis närvide rahustuseks tasub kuulata teise naise kogemust ;) Palju lihtsam on nii, kui täielikus tundmatuses ei pea üksi ekslema.
Digital Health Talks - Changemakers Focused on Fixing Healthcare
AI in healthcare is starting to deliver on its promise, from Epic's ambient documentation tools to a new AI model pulling fresh insights out of routine sleep studies. Megan Antonelli and Janae Sharp break down the good news in healthcare technology this August, plus a few reality checks along the way.How Epic's AI-generated summaries and ambient listening tools are reducing documentation burden at Mayo Clinic, Parkview Health, and Riverside HealthWhy a recent study found burnout reduction from ambient AI wasn't as strong as expectedHow UC Davis is expanding telehealth access with a new tele-nephrology program and an at-home HPV testing pilot with Teal HealthWhat Cleveland Clinic's new AI model can detect in routine sleep study dataWhy "AI slop" is becoming a bigger conversation in healthcare content and marketing, and what LinkedIn is doing about itJanae Sharp, Founder, The Sharp IndexMegan Antonelli, CEO, HealthIMPACT Live Subscribe to Digital Health Talks on Apple Podcasts, Spotify, YouTube, or wherever you listen.Learn more about HealthIMPACT Live events, virtual forums, and healthcare leader conversations at healthimpactlive.com.Interested in being a guest, sponsoring, or joining the HealthIMPACT community? Visit healthimpactlive.com/digital-health-talks.
This week, primary care experts Drs. Kate Rowland, Gary Ferenchick, Mark Ebell and Henry Barry discuss 4 new studies: The post-Papanicolau era of HPV self collection, electroacupuncture for post-herpetic neuralgia, AI-based app for melanoma detection, and the onset age of silent atherosclerosis. Links:Self-collected HPV: https://pubmed.ncbi.nlm.nih.gov/42509175/ Electroacupuncture: https://pubmed.ncbi.nlm.nih.gov/42189557/ AI skin cancer app: https://pubmed.ncbi.nlm.nih.gov/41701029/ Silent plaques: https://pubmed.ncbi.nlm.nih.gov/42670946/
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3vu —— 以上為 Firstory Podcast 廣告 —— 加入會員，支持節目： https://masterstrangehistory.firstory.io/join留言告訴我你對這一集的想法： https://open.firstory.me/user/ck7jykyq8abn60873daiihxpk/comments【奇異碩士】在空中陪伴你的週日早晨！ 每週日早上八點到九點，寶島聯播網 - 北部寶島新聲FM98.5、中部大千電台99.1，和你一起討論歷史和時事的話題！ https://www.baodaoradio.com.tw/ 【奇異碩士】EP. 075 小粉紅其實很好戳？ 回覆留言：腦內啡不斷轟炸的短影音時代，留言也是未看先噴！
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep47e —— 以上為 Firstory Podcast 廣告 —— 主持人：丸子來賓：北斗奠安宮 吳季冰秘書長加入會員，支持節目： https://careradio.firstory.cc/join留言告訴我你對這一集的想法： https://open.firstory.me/user/ckfxksqylr84j08000h3ze64h/comments Powered by Firstory Hosting
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep47e —— 以上為 Firstory Podcast 廣告 —— 主持人：林水木藥師來賓：彰化基督教醫院 陳藥師加入會員，支持節目： https://careradio.firstory.cc/join留言告訴我你對這一集的想法： https://open.firstory.me/user/ckfxksqylr84j08000h3ze64h/comments Powered by Firstory Hosting
Neste episódio, Graciele e Tabata conversam com a professora doutora Luísa Lina Vila – bióloga com 30 anos de pesquisa em HPV, vírus do papiloma humano (ou papilomavírus humano). Decubra porque a vacina contra o HPV é o maior preventor do câncer de colo de útero, entre outras doenças. Ajude o Pirula https://www.vakinha.com.br/vaquinha/pirulla Links do […]
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3tt —— 以上為 Firstory Podcast 廣告 —— ✰✰✰《射後不理#爽就好了》2026 訂閱方案，解鎖所有集數：https://dtshop.vip/subscription01 ✰✰✰—————— ฅ՞• •՞ฅ ——————[本集重點]✰ 來賓 陶器男孩 宇成 @jeremy.y.c☛ 加入一段原本就很穩定的關係不容易！除了獲得雙倍的愛，卻也有雙倍的事要磨合☛ 當其中一人感到被冷落或產生不安全感時，彼此的親密感和距離感要怎麼拿捏？☛ 雖然說三人相愛彼此地位應該相等，但從嫉妒到三人平衡需要花費大量溝通成本☛ 在一段關係裡如果比單身時還要壓抑、不開心，不如選擇自己一個人比較舒服自在☘︎ 宇成的陶藝品牌 Fusion Ceramics (@ceramicsfusion)⊗ 未滿18歲請勿收聽 ⊗—————— ฅ՞• •՞ฅ ——————✰ 訂閱 & 分享給就是對我們最好的支持 ☛ 官網：https://dt-talk.com/☛ 射粉電子報：https://lihi1.me/AKkAT☛ 集體蕭貪之好康射給你【射後團購群】：https://lihi2.com/iyzOR （通關密碼：1069）✰✰ 歡迎乾爹乾媽來包養 ☛ 廠商合作請來信：dttalk@dt-talk.com ✰✰✰ 聊得喉嚨好乾，心有餘力的話就請我們吃川貝枇杷膏吧！☛ 捐款連結：https://dt-talk.com/support (點選單次付費即可捐款） Powered by Firstory Hosting
In episode 86 of Going anti-Viral, Dr Brenda Crabtree-Ramírez joins host Dr Michael Saag to discuss women and HIV in Latin America. Dr Crabtree-Ramírez is a Professor of the HIV Program at the Universidad Nacional Autónoma de México. She has participated in Phase I to IV clinical trials evaluating therapies for HIV/AIDS and opportunistic infections and is the Principal Investigator in Mexico for the Caribbean, Central, and South America Network for HIV Epidemiology (CCASAnet). She has contributed to studies focused on sociodemographic factors, HIV-related comorbidities, women with HIV, aging with HIV, and advanced HIV disease. Dr Crabtree-Ramírez discusses the HIV epidemic in Latin America, focusing on women's unique challenges, access to care, and prevention strategies including PrEP and HPV vaccination. 0:00 – Introduction 1:36 – Challenges in HIV research and healthcare access in Latin America4:08 – Access to antiretroviral therapy and diagnosis gaps5:15 – Unique challenges faced by women with HIV and testing during pregnancy 8:11– Research on women and HIV in Latin America11:50 – CCASAnet and IeDEA network: data collection and insights13:46 – Barriers to care for women: transportation, stigma, and violence17:18 – Strategies to improve diagnosis and engagement in care20:57 – Prevention strategies: PrEP and community programs24:06 – Role of HPV vaccination and cervical cancer prevention26:44 – Future directions and women's leadership in HIV research and call for continued advocacyResources:CCASAnet: https://www.ccasanet.org/IeDEA: https://www.iedea.org/ __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...
Broadcast from KSQD, Santa Cruz on 9-03-2026: With CDC vaccine guidance politically contested, major medical societies (AAFP, AAP, ACOG, IDSA) issued their own recommendations through the Vaccine Integrity Project. Dr. Dawn recommends flu shots in October for peak Thanksgiving antibodies, high-dose flu vaccine (not adjuvanted) for frail seniors, and COVID/flu/RSV given at the same visit—except delay COVID vaccination four to six months after recent infection. Pregnant women should receive RSV vaccine at 32-36 weeks, and infants under eight months entering their first RSV season need vaccination if the mother wasn't vaccinated. RSV is one-time only for adults 75+, or for high-risk 50-74-year-olds. Measles is the most contagious human disease, transmissible through brief incidental contact (buses, taxis, carnival rides). Beyond acute mortality (one in 5,000 pre-vaccine), survivors face rare but catastrophic subacute sclerosing panencephalitis 10-40 years later—immune-mediated brain destruction comparable to Huntington's. Thirty percent of current outbreak cases are in adults reflecting decades of under-vaccination in certain communities, and pregnant unvaccinated mothers create a dangerous one-year window since the live vaccine cannot be given during pregnancy. Inlicitide (brand name Lipithandra) is the first oral PCSK9 inhibitor for LDL reduction, priced at $315/month versus $600 for the injectable version. Dr. Dawn positions it strictly as a treatment—not preventive—drug for patients who've had a heart attack or equivalent event and cannot achieve target LDL on statins alone, with prior authorization typically successful given documented disease. Updated cancer screening guidance from major societies: cervical cancer screening at 25 for HPV-vaccinated women (earlier if unvaccinated), annual mammograms from 45-54 then biennial, PSA screening starting at 50, and low-dose CT lung cancer screening at 50-80 for heavy smokers. Dr. Dawn pushes back on the 2018 Task Force downplaying of PSA screening, noting MRI-targeted transperineal biopsies have dramatically reduced false-positive complications. She also warns about rising male cancer diagnoses at later stages for stomach, lung, tongue, and throat cancers, and recommends the vinegar test for suspicious oral white spots. Parkinson's disease develops through a decades-long prodromal phase before motor symptoms appear—by tremor onset, at least half the substantia nigra neurons are dead. Four early warning signs: persistent loss of smell (90% of Parkinson's patients experience this up to 20 years before diagnosis; free scratch-and-sniff cards available from The Michael J. Fox Foundation), REM sleep behavior disorder (acting out dreams; 50-70% develop Parkinson's or Lewy body dementia within 5-10 years, 130-fold higher risk if over 50), chronic constipation (possibly linked to gut microbiome production of misfolded alpha-synuclein), and orthostatic hypotension. Available diagnostics include alpha-synuclein seed amplifier assay (CSF), skin biopsy, and DaTscan SPECT imaging (typically covered with "clinical uncertainty" documentation). A caller with insomnia asks about using vinegar to clean his new CPAP machine. Dr. Dawn recommends one part white vinegar to three parts warm water, then rinsing—or unscented Dr. Bronner's castile soap. She emphasizes avoiding bleach, alcohol, ammonia, scented soaps, and moisturizers, since mold prevention is the primary cleaning goal. Columbia University's STAR (Sperm Track and Recovery) AI system, inspired by astronomical star-detection algorithms, hunts vanishingly rare sperm in men with azoospermia by streaming semen through a hair-thin channel imaged 300 times per second. A robotic arm extracts flagged cells within milliseconds. Of 175 patients tested, 30% had recoverable sperm, and the system produced its first baby late last year for a couple with 20 years of infertility.
Credits: 0.75 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com Episode resource links: Zhou H et al. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355. eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884 Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041 Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257 Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930. Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541. Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.: American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022. Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485. Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455 Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666 Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301. Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015 Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024 Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0 Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575 Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1 Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
This episode highlights FDA approval of the first-in-class RAS inhibitor daraxonrasib for metastatic pancreatic adenocarcinoma, concerning gaps in cervical cancer screening and HPV vaccination among younger women, and new evidence defining which patients may benefit most from coronary artery calcium scoring alongside the PREVENT cardiovascular risk calculator.
This week Elle and Vee welcome Boyslut author Zachary Zane back for a conversation that goes everywhere. From male bisexuality and the stigma that still exists even in sexually open spaces, dick-size insecurity, HPV and sexual health disclosure, to why being open with your doctors actually matters. Zachary also takes listeners inside his very slutty week on Fire Island, shares his first Top Floor experience, and gets real about sexual confidence, enthusiastic lovers, and communicating how you experience pleasure. It's an unfiltered conversation about being sexual, being proud of it, and creating more space for everyone to want what they actually want.Website: zacharyzane.comSubstack: zacharyzane.substack.comBook: BoyslutInstagram: @zacharyzane__________________________
In this episode of the Hope Natural Health Podcast, Dr. Erin Ellis talks about why so many women dread Pap smears and how a difficult or painful past experience can lead to years of avoidance. She breaks down the importance of cervical cancer screening, current screening guidelines, HPV, vaccination, and the newer at-home HPV self-collection options that may make screening more accessible and comfortable for some women. In This Episode, You Will Learn: Why a difficult or painful past experience can make women avoid Pap smears and pelvic exams for years Why cervical cancer screening is important, even when you feel completely healthy and have no symptoms How often women actually need cervical cancer screening and the differences between HPV testing, Pap testing, and co-testing How at-home HPV self-collection works and how it may make screening more comfortable and accessible What a positive HPV result means, including why it does not automatically mean you have cervical cancer and why follow-up care is still important How HPV vaccination, regular screening, and a supportive Well Woman Exam can all play a role in protecting your cervical health For more on Dr. Erin: Schedule a Well Woman Exam with Dr. Erin: https://hopenaturalhealth.practicebetter.io/#/619ef36b398033103c7b6bf9/bookings?s=61bbf0633980331230a27d04&step=date Work with Dr. Erin here: https://p.bttr.to/3E88ps4 Buy Dr. Erin's Supplements here: https://drerinellis.com/shop Get the Period Productivity Planner here: https://www.amazon.com/dp/B0BBYBRT5Q?ref_=pe_3052080_397514860 Download the FREE Menstrual Cycle Nutrition Guide here: https://detox.drerinellis.com/ Watch The Free Video "7 Hormones Affecting Your Weight Loss Goals" here: https://weightloss.drerinellis.com/ Let's Be Friends: Follow Dr. Erin on Instagram: https://www.instagram.com/dr.erinellis/ Follow Dr. Erin on Facebook: https://www.facebook.com/drerinellisnmd Follow Dr. Erin on TikTok: https://www.tiktok.com/@dr.erinellis?lang=en Join the Free Hope Circle Community: https://hormonehealingproject.drerinellis.com/communities/groups/the-hope-circle/home?invite=69120d498b7e3f60397656b8 Bookmark Dr. Erin's Website: www.drerinellis.com Subscribe to Hope Natural Health on YouTube: https://www.youtube.com/channel/UChHYVmNEu5tKu91EATHhEiA Follow Hope Natural Health on FB: https://www.facebook.com/hopenaturalhealth Sign up for Newsletters here: https://booking.hopenaturalhealth.com/widget/form/VUubL7MNYELduwQL8ssI
Credits: 0.75 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com Episode resource links: Zhou H et al. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355. eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884 Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041 Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257 Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930. Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541. Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.: American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022. Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485. Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455 Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666 Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301. Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015 Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024 Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0 Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575 Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1 Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Reproductive health is a part of women's health throughout every stage of life, yet so many of us still have questions about what preventative care we actually need, when we should be getting screened, and what our options are when it comes to our bodies and our healthcare. In this episode, we're having an open, honest, and judgment-free conversation with Jennifer Love, a certified nurse midwife and Lead Clinician at Planned Parenthood of Southern New England. With more than 20 years of experience in reproductive healthcare and over a decade at Planned Parenthood, Jen brings a science-based, evidence-based, and patient-centered perspective to some of the most important topics women need to understand. We're breaking down cervical cancer screenings, including what Pap tests and HPV testing actually look for, why routine screening matters, and what women should know if they've been putting off an appointment. We're also talking about STI testing and treatment — why someone can have an STI without symptoms, how testing works, and why getting tested should be viewed as a normal part of taking care of your health rather than something associated with shame or judgment. And we're having an honest conversation about abortion care, including the differences between medication abortion and procedural abortion, what each experience can look like, and how healthcare providers help patients understand their options and make informed decisions about their care. Most importantly, this conversation is about access, education, prevention, and empowering women to feel comfortable asking questions about their own bodies. Whether you're overdue for a screening, wondering when you should get tested, trying to understand your reproductive healthcare options, or simply want reliable information from a medical professional, this episode is designed to give you straightforward answers without the stigma. No shame. No judgment. Just facts — and a reminder that taking care of your reproductive health is taking care of yourself.
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3vu —— 以上為 Firstory Podcast 廣告 —— 加入會員，支持節目： https://masterstrangehistory.firstory.io/join留言告訴我你對這一集的想法： https://open.firstory.me/user/ck7jykyq8abn60873daiihxpk/comments【奇異碩士】在空中陪伴你的週日早晨！ 每週日早上八點到九點，寶島聯播網 - 北部寶島新聲FM98.5、中部大千電台99.1，和你一起討論歷史和時事的話題！ https://www.baodaoradio.com.tw/ 【奇異碩士】EP. 074 時代倒退是你要的嗎？回覆留言：共和制度太爛了？不如回去專制政府？你... 認真？
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep45r —— 以上為 Firstory Podcast 廣告 —— 吉時保： https://fstry.pse.is/9mmpuu 免指定車牌、車型，用車前1小時投保，手機投保5分鐘新安東京海上產險｜0800-369-168｜104台北市中山區南京東路三段130號8-13樓 —— 以上為 Firstory Podcast 廣告 —— 你各位啊 低聲詠唱吧 Powered by Firstory Hosting
Send us Fan MailRoutine cancer screenings have been proven to lead to better health outcomes and an increase in survival rates in the U.S. Finding cancer before it spreads can significantly improve outcomes. Bayless Drum, M.D., generalist in obstetrics and gynecology with Texas Tech Physicians and an assistant professor with the Texas Tech University Health Sciences Center School of Medicine, explains that Pap smears detect cervical cancer and precancerous changes and how new screening recommendations have changed leading to a decrease in frequency. She emphasizes the importance of screenings and the HPV vaccine, which can reduce the risk of cervical cancer. Dr. Drum also assures us that while these exams might be uncomfortable, they're important for early detection and prevention.
Credits: 0.75 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com Episode resource links: Zhou H et al. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355. eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884 Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041 Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257 Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930. Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541. Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.: American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022. Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485. Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455 Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666 Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301. Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015 Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024 Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0 Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575 Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1 Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Credits: 0.75 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com Episode resource links: Zhou H et al. Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355. eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884 Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041 Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257 Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930. Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541. Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.: American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022. Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485. Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234. Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455 Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666 Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301. Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015 Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024 Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0 Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575 Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1 Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Como as novas diretrizes da Sociedade Europeia de Cardiologia, a autocoleta domiciliar no rastreamento cervical e o enfrentamento de surtos infecciosos transformam o cuidado em saúde? Neste episódio do Afya News, analisamos a primeira diretriz da ESC totalmente dedicada à reabilitação cardiovascular, estabelecendo-a como intervenção multidisciplinar precoce para diversas condições, incluindo a cardio-oncologia. Discutimos também a expansão do programa do NHS na Inglaterra com kits de autocoleta de HPV entregues em domicílio para superar barreiras de acesso e diagnosticar o câncer cervical precocemente. Por fim, apresentamos no Radar a gravidade epidemiológica do surto de Ebola na República Democrática do Congo, que já registra milhares de óbitos e reforça a urgência de medidas de biossegurança. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:https://portal.afya.com.br/podcasts/afya-news/31-08-2026 Conteúdo 100% validado por equipe médica.Médico Responsável: Dr. Guilherme Rodrigues — CRM-RJ 1049461.
Women who have missed a cervical screening appointment in England are to be offered HPV self-testing kits by the NHS. Over the next year, nearly four million women will receive invites on the NHS App or via text message, email or letter to order a free kit to use at home. The aim is to encourage more women to complete their potentially lifesaving screening to detect HPV, which can increase the risk of cervical cancer. Dr Sue Mann, National Clinical Director for Women's Health in England and a consultant in Sexual and Reproductive Health, joined Nuala McGovern.For more than a decade, armed gangs in northern Nigeria have repeatedly targeted schools, kidnapping children for ransom and forcing some educational establishments to close. BBC journalist Yemisi Adegoke has recently returned from the state of Zamfara, where ongoing insecurity has left many girls unable to attend school, threatening their futures. She talks to Anita about her experience.After the death of both her parents, best-selling novelist Louise Doughty made a startling discovery whilst clearing out the family home. Inside a black suitcase, she stumbled upon a treasure trove of letters that revealed the origins of her parents' love affair. She joined Nuala to discuss her first memoir On This Spot Fell One Tear of Love described as a portrait of grief and loss and family – and a love story.Presenter: Anita Rani Producer: Annette Wells
In this episode of Behind the Genes, we explore how personalised cancer vaccines are being developed, and how genomics and AI could help make these treatments more precise. Our host, Florence Cornish is joined by: Dr Victoria Goss, Associate Professor of Early Diagnosis and Translational Research at Southampton Clinical Trials Unit and head of the Southampton Clinical Trials Unit Cancer Vaccine Launchpad team Professor Lennard Lee, Associate professor at the University of Oxford, Consultant Medical Oncologist, NHS Ali Richards, a participant who took part in a cancer vaccine clinical trial Together they discuss how cancer vaccines train the immune system to recognise cancer, how genomic information can help identify the unique features of an individual's tumour, and how AI could help researchers analyse genomic data and accelerate the development of new cancer vaccines. “The reason I said yes was because my treatment really was punishing. It was so many side effects to it. The cancer never made me feel sick, but the treatment made me really sick. So I said yes because I just wanted to help other people not have to go through what I went through.” Transcript [00:00:00] Florence: What if a vaccine could help treat cancer? Hello and welcome to Behind the Genes, the podcast that brings you the stories, research, and innovations shaping the future of genomic healthcare. Today, we're going to be talking about cancer vaccines, how they're being developed with the help of AI, what role genomics has to play, and what it could mean for patients. [00:00:23] Florence: I'm Florence Cornish, and joining me today we have Dr Victoria Goss, who leads cancer vaccine research at Southampton Clinical Trials Unit; we have Professor Lennard Lee, who is a medical oncologist and Associate Professor at the University of Oxford; and Ali Richards, who took part in the Southampton Cancer Vaccine Programme. [00:00:45] Florence: I think before we get into cancer vaccines specifically, it might be good to start with the basics. So vaccines are something most of us have heard of and probably experienced as well, but we don't always necessarily understand how they work. So Lennard, can I come to you to explain what a vaccine actually is, how it works with our immune system, maybe at the most basic level for those who might not have a scientific background? [00:01:19] Lennard: Thanks, Florence. What's a vaccine? Very, very simply, something that protects your body from disease. We've had a few when we were younger, like which protects you against meningitis or hepatitis or different types of infections that can affect children. [00:01:36] Lennard: And it really does show that your immune system is really powerful. Every day, it looks around trying to work out what's there which shouldn't be there and takes care of it. And ideally, your immune system just works in the background without causing any problems. And so what a vaccine does is it really helps the body understand something that's abnormal. [00:01:55] Lennard: And the vision here is that you can use this technology to hopefully patrol against cancer, because half the people out there will never get cancer. They are the maybe the lucky ones or maybe the ones with a good immune response. And so a vaccine is basically giving your immune system a wanted poster: [00:02:11] Lennard: "This is what threat looks like. This is what you need to control". [00:02:16] Florence: And I think you mentioned some great examples there. There are lots of common examples of vaccines people might have heard of. I think maybe the flu vaccine is probably a common one that people are thinking about in the wintertime. I think another one is maybe the HPV vaccine. [00:02:29] Florence: Lennard, could you explain a bit more to our listeners about the HPV vaccine? What it is, how it works? I think people often think of it as a type of cancer vaccine, but actually it's targeting a virus. Is that right? [00:02:41] Lennard: Yeah, that's correct. So this is now a vaccine which has been rolled out across the NHS, and it's actually worked really well to get rid of a few cancer types, which is incredible. [00:02:51] Lennard: And why is that important? Well, cancer can be caused by many, many different things. Sometimes it's because you've done things like smoking or weight plays a role or just bad luck or the genes that you've inherited. But some cancer types are caused by viruses. And so many people nowadays are getting the HPV vaccine to stop cancer types like cervical cancer, hopefully head and neck cancer, and many of the rarer cancer types. [00:03:21] Lennard: And so again, what you're doing here is you're taking the immune response, telling it the body shouldn't get this virus and hopefully prevent some of the bad consequence of getting this viral infection, like cancers. [00:03:33] Florence: Thank you. That's really helpful to understand. So we've talked about how vaccines can be used to treat viruses, and I think most of us, when we hear the word ‘vaccine', we probably do associate it with something that stops us from getting ill. [00:03:46] Florence: Victoria, could you tell us about how vaccines could be used to treat cancer? [00:03:50] Victoria: Yeah, absolutely, and it is great to be here today. Thank you. So Lennard's already sort of spoken about preventative vaccines, and when we think about cancer vaccines, we're thinking about therapeutic vaccines. So we're thinking about training the immune system to recognise the cancer as something that needs to be dealt with because cancer is really tricky because it's our own cells that have gone wrong, if you like. [00:04:16] Victoria: But that means it also is very good at evading those signals which tell the immune system that it needs to be cleared. So the analogy that Lennard has already given of a cancer vaccine sort of creating a wanted poster sort of builds on an analogy from one of your previous podcasts where they described the immune system as like the police almost trying to catch criminals, which are the cancer cells. [00:04:41] Victoria: And the cancer vaccine analogy builds on that. So you've created a wanted poster which is training and giving the police more information about what those cancer cells look like. And then when we think about building on that with sort of personalised cancer vaccines, which is an incredibly exciting step when we think about the development of how cancer vaccines can be used, sort of really individualised therapy going forward, that wanted poster gets even more specific. [00:05:07] Victoria: It's almost like giving a phone number or an address for that specific cancer type that is very specific to that patient. So the therapeutic vaccine is, is targeting the immune system. It's training our immune system to recognise the cancer as something that needs to be dealt with. [00:05:26] Florence: It's funny you mentioned that analogy because I was just about to point listeners to that episode. If anyone wants to learn more about cancer vaccines specifically, you can check out our previous Genomics 101 podcast episode called ‘What Are Cancer Vaccines?' So Ali, I think I'd love to bring you in at this point because you have experienced this from the patient side of things. [00:05:49] Florence: Could you tell us a little bit about your journey, your cancer diagnosis and treatment, and maybe more about the clinical trial you were part of, if you feel comfortable sharing that? [00:05:57] Ali: Yeah, sure. Hi, Florence. It was Christmas 2015, and I felt a lump in my neck. And maybe because I'm a woman and we're always taught to treat lumps seriously, in the January I made an appointment with the GP, and she very quickly fast-tracked me through to the hospital. [00:06:19] Ali: And January 2016, I got a diagnosis. It was a tumour on the base of my tongue at the left, and I was told it was caused by a variation of the HPV virus. So yeah, that was all a bit of a shock. I was shocked and I was scared, but I was also really angry because I look after myself. I eat well, all those things. [00:06:45] Ali: It's just bad luck that it was a virus that my body couldn't deal with. I just, I felt guilty as well because of what I was gonna put the family through. So I had various scans and tests. I had an operation to remove my tonsils, although we soon discovered there weren't any left anyway. And they took a biopsy, which I didn't know at the time, but turned out to be important later on for the trial. [00:07:15] Ali: Then I had to have a whole load of prep beforehand because of the impact of the treatment. So I had to have restorative dentistry, audiology tests. I had a PEG fitted, that's a feeding tube, in my stomach, and I thought, "Surely it's not going to be this bad." But that PEG, that feeding tube was a blessing in the end. [00:07:40] Ali: And I had a mask made, and the mask fits you and basically pins you down to the radiotherapy table so you don't move when... because it's very precisely targeted at your tumour. So yeah, I went on to have five sessions of chemo, which felt quite easy. The radiotherapy was the really, really tough part. I had, uh, seven weeks of it, 35 sessions. [00:08:08] Ali: So that was, yeah, that was a challenge. [00:08:11] Florence: Thank you, Ali. Thank you for sharing that. I think it's always really valuable to get that patient perspective when we're talking about things like this. Lennard, I wanted to come back to you now to talk about the different types of vaccines that exist and which ones are being used specifically in the treatment of cancer. [00:08:30] Lennard: Um, thanks, Florence. And Ali, are you 10 years now down the line since your diagnosis? [00:08:34] Ali: Yeah, it feels good. [00:08:37] Lennard: Congratulations. [00:08:38] Ali: Yeah, yeah. It feels good. I really valued the follow-up checks that I had, both from my oncologist, but also I got some through the trial, and it really helped restore some confidence in myself and my body to deal with things and to be able to move on as well. [00:08:56] Lennard: Oh, well done. That's fantastic because you telling us that story just really brings it to life about how scary this can be and also the fact that you had to go through all those sessions, thirty-five sessions and, um, and now you're 10 years down the line and still talking and giving hope- [00:09:11] Ali: Yeah ... [00:09:11] Lennard: that new technology still comes, so thanks, Ali. [00:09:13] Ali: That's a pleasure. [00:09:14] Lennard: Um, yeah, so Frances, this is what's really exciting. What types of vaccines are there? Well, first thing to say is that we're really good in this country about vaccine research. If you look around the world, what are we good at? Well, everyone knows that we developed the pandemic vaccine, and actually that technology is something that we can control. [00:09:31] Lennard: We're world leaders at. It's quite cheap technology, and it's something that we are really good at bringing to patients. And Ali's our testament where she got on the trial, she helped test it and really pioneered new ways of research. So what types of vaccines are there? Well, I think we talked to the first bit where Victoria taught us that some of them can treat cancers and some of them can maybe prevent cancers. [00:09:53] Lennard: And the HPV's one which is maybe be able to do both one day, which is brilliant. What would like... what else do people know about? Well, people might know that there are different types of technologies. So if we think back a few years now, back to 2020, there are some which are viral-based, and some which are mRNA based. [00:10:12] Lennard: Both of these were new technologies which the whole population of the world came together to create and some of them are peptide-based. So there's probably three different types here. The protein ones or peptide one, which you always had, and then in the last five years, it's an incredible time to be alive, where new vaccine technology comes through, it's more effective and safer. [00:10:32] Lennard: These are the viral ones and mRNA ones, and everyone's now pursuing all of these to try and make sure that we can maybe treat cancer in future. [00:10:41] Florence: Can I possibly pick your brain a little bit more about the mRNA ones specifically? I think as you mentioned, lots of people might have heard of those during COVID. [00:10:50] Florence: Could you maybe explain a little bit more about those and how they work? [00:10:53] Lennard: Yeah. So this is going to take us all the way back to GCE biology now. If you remember - and we are Genomics England, so we, we got to work out why genomics is important, and we'll probably get to this. But remember, genes make RNA, which then makes protein. [00:11:11] Lennard: And so if you're trying to reprogramme the immune response, you could give your body a protein, the back end of it. You can maybe give it an RNA, which is a blueprint too. And so what an mRNA vaccine is, it's a way of giving the blueprint or the instructions to the body of what to recognise, what the cancer looks like, um, um, or what the virus looks like, and target it. [00:11:32] Lennard: If you want the analogy, well, for those people who had the pandemic vaccines, the ones which was mRNA based was, uh, the Pfizer one, and that worked really, really well. Cheap to make, easy to produce, and, uh, it's just a jab. And so people are now exploring that for cancer treatment now. Take new technology, which has only been developed five years ago, technology, which is just a blueprint, cheap to make, easy to update, and now we're targeting cancer. [00:11:59] Lennard: Um, so that's basically what an mRNA vaccine is, giving the body the blueprint or the instruction of what a cancer looks like and trying to target that cancer. [00:12:08] Florence: And you kind of alluded to it a little bit in your answer, but, um, it would be good to know more about where genomics comes into all of this. You know, why is it such an important part of developing vaccines? [00:12:18] Lennard: And that's a great question, and really comes back to our second strengths, which is that we're really good at vaccine research, and yet we are also world leaders at genomic research. It's a really exciting time because, um, when Victoria and me and Ally at school, we would-- we, we learnt about that race to sequence the first human genome. [00:12:38] Lennard: It was really exciting because for the first time, we can see every single genetic base in every human, and that used to cost billions of pounds to do that, and it would take many months or years to do that Fast-forward a few years, and then now Genomics England delivered the next success for humanity. [00:12:57] Lennard: I think it was about 2015 to 2017 where they, they did 100,000 Genome Project, where the UK led the world in sequencing 100,000 people, including people with cancer, to try and understand what caused their cancer, what the risk factors are. And why is that relevant now? Well, it's because if you know what a cancer looks like, then you know what the abnormality is, well, then you can vaccinate against it. [00:13:22] Lennard: So we've now gone from this amazing arc of discovery here, where when we were at school, we worked out what the human genome looks like. We can sequence it end to end and see in all its detail. Then a, an amazing organisation came out the ground called Genomic England, which shows that you can run it in the NHS. [00:13:39] Lennard: 100,000 people could do it. And now we're making the next big jump now, which is it's not just going to give you a diagnosis, but maybe becomes a drug and a vaccine in future. And actually, probably it already has because Ali's that example, a success example of it happening. [00:13:54] Florence: Yeah, I wanted to actually ask you about that, Ali. [00:13:56] Florence: So just as you were saying, Lennard, it kind of... The cancer vaccine sounds quite futuristic, but as you said, it's, it's sort of already happening. So Ali, do you remember kind of how you first heard about the cancer vaccine trial? [00:14:11] Ali: Yeah. I had a bit of an unfortunate time because after all that radio and chemo, my cancer still hadn't gone, and I had to have an operation to remove lymph nodes. [00:14:22] Ali: But my oncologist at Poole Hospital, who's a fantastic woman, she had been involved, unknown to me, in the some of the thinking behind the trial, and particularly that she could recruit people because they were sat in her office. So she asked me if I'd like to take part, and without knowing anything, I said yes. [00:14:49] Ali: And the reason I said yes was because my treatment really was punishing. It was so many side effects to it. The cancer never made me feel sick, but the treatment made me really sick. So I said yes because I just wanted to help other people not have to go through what I went through. I didn't really understand it, if I'm perfectly honest. [00:15:16] Ali: I didn't really know what was going on, but then I'm not, you know, a super brain like Lennard and Victoria. I knew that I just wanted to do something to help people going forward, not having to deal with the same. So yeah, I put my hand up and there I was on the trial. [00:15:37] Florence: So you mentioned there the, the really horrible side effects that you got from your original treatment. Did you have, um, what was your experience with side effects with the vaccine? Was it similar? Was it different? [00:15:47] Ali: Oh, no, the, the vaccine was like a holiday compared to the treatment. Absolutely. At, at worst, in the first few treatments, you felt a bit like you had a cold, bad cold coming on, maybe slightly flu-y, but you took, you were given Ibuprofen at the same time as you had the vaccine. [00:16:10] Ali: So no, it, the treatment with the vaccine was an absolute breeze. Which is kind of like, yes, this is what I want for people. You know, not, not the radiotherapy, not the chemo. So yeah, it was, it was really very easy by comparison. [00:16:29] Florence: Oh, I'm so glad to hear that that was your experience. I'm just curious now also, was there anything that surprised you about the trial? [00:16:35] Florence: You said there that you didn't really, like, have an understanding of cancer vaccines. You, you agreed to it straight away. Was there anything that maybe, like, you weren't expecting or surprised you? [00:16:45] Ali: I think it surprised me that it was really quite easy. [00:16:48] Florence: Yeah. [00:16:49] Ali: Uh, I was delighted to have the team I had looking after me because they were fantastic. It all felt very simple. [00:16:59] Ali: And how nice that was. You know, if I could've had that instead of all my previous treatments, um, it would've, it would've made everyone's life so much easier. And I guess, I don't know about the cost of drugs, but I guess the cost to the NHS would've been less because I wasn't in and out of hospital, I wasn't having to have all these extra things done, and all this extra support like dieticians and so on because I had to have my feed tube replaced. [00:17:35] Ali: So all of that is impacts on the NHS, whereas this was very simple. [00:17:40] Florence: I wanted to come to you now, Victoria, and ask you about the outcomes of this trial that Ali took part in or other trials like it, and whether we know yet what the broader implications of, of these advances might be. [00:17:55] Victoria: So I think what we need to think about when we're thinking about developing these treatments and sort of evaluating the treatments at each stage is that it goes through a very clear pathway of progression, and Ali was involved in one of the, the earliest stages of that progression. [00:18:09] Victoria: And it's, it's always amazing to me to hear your story, Ali, and to know that patients are willing to take part in the research and that's what allows us to develop these treatments. So the trial that Ali was part of has now gone on to develop into a, a larger scale study which will be evaluated again. [00:18:27] Victoria: And that all starts to form the evidence for how these treatments can be shown to be effective, and also how they can show... Also, you know, Ali's already touched on there about the cost implications, so how we can show that that can be beneficial as well. And then we can start to think about how they can be taken up and become part of routine standard of care for patients like Ali, as she was describing. [00:18:50] Victoria: And all of that evidence comes together, which then gets evaluated and then it, and then it moves forward through that progression. But it's-- we have very clear, um, you know, a, a route that each new, new treatment has to go through, um, to be able to, to become part of standard of care. [00:19:07] Florence: And Victoria, you also play a key role in the Cancer Vaccine Launchpad. [00:19:12] Florence: For any listeners who might not be familiar with the Cancer Vaccine Launchpad, could you maybe tell us a little bit more about it? [00:19:18] Victoria: Absolutely. So in its simplest terms, the Cancer Vaccine Launchpad is designed to help find patients who might be eligible to take part in trials like the one that Ali was part of. [00:19:30] Victoria: It's an incredible project. Cancer Vaccine Launchpad is quite long, so we tend to abbreviate it to the CVLP, which I'll do from now on, if that's okay. The CVLP to me really demonstrates the power of collaboration because it's brought together so many different teams that have been necessary to make sure that, that what we're trying to achieve, so finding as many patients as possible for these trials, is possible. [00:19:52] Victoria: We deliver this project on behalf of NHS England. I know that Lennard was involved right from the start as well. The reason that we need the CVLP is because one of the biggest challenges in research of these new treatments is finding the patients who might be eligible. So one of the reasons for that is because when we are running the trials to test these new treatments, there's a lot of different infrastructure that's needed to support the delivery of those trials. [00:20:19] Victoria: So you need special pharmacy services, special research nurses. All of that has to come together to be able to deliver trials of new treatments. And actually, that means that actually those studies can often only take part in a small number of hospitals. So historically, you only had the opportunity to take part in those trials if you lived near one of those hospitals, which is, you know, like Ali did. [00:20:42] Victoria: So what the CVLP is, what, what it has done, it has created a formalised network which enables referrals to happen from ... we're opening 83 hospitals now across England. We've just expanded out to the devolved nations as well, which is a really exciting development, and it creates that, that network which allows patients who might live further away from a hospital delivering one of those vaccine or immunology trials to be able to be referred in to see if they might be eligible. [00:21:09] Victoria: So essentially, it's a bit like creating a big funnel. So you're finding all of the potentially eligible people that could take part in that trial, and you're funnelling them into the trial site to find those patients who are eligible. [00:21:22] Florence: And what impact do you hope that this could have for the NHS and also for, like, individual patients as well? [00:21:29] Victoria: So we've seen such positive results from the CVLP so far. The first study that we worked with was for a colorectal cancer vaccine trial. Before the CVLP started working with this trial, only 17% of the eligible patient population in England had the opportunity to take part because they lived near one of those hospitals delivering the trial. [00:21:52] Victoria: After the CVLP started working with it, we had increased that to over 60% of the eligible patient population. So you could really see how it has expanded out access, and that's just a fantastic opportunity to be able to bring, to bring patients. We also were able to show that the UK was screening, so looking for patients at three times the global average. [00:22:14] Victoria: So we really were able to see how the CVLP is supporting and accelerating recruitment to those trials I think the key thing for me has been the patient enthusiasm that we have seen though. So when we open up to a new trial where, that the CVRP is working with, we are always inundated with people who contact us to find out how they can be part of this network because they want the opportunity to take part. [00:22:40] Victoria: We know that some patients have travelled for two hours to a trial site to find out if they could be eligible because actually they want the opportunity. So the CVRP has really sort of enabled that patient choice, which is a fantastic thing to be able to do. But it also builds on what Lennard was talking about earlier, which is the UK is really good at this research and actually what the CVRP is then doing is showing how we can really support recruitment to these trials to accelerate these trials and that only brings more trials to the UK which again creates more opportunities for patients which is exactly what we're trying to do. [00:23:14] Victoria: We're trying to create more and more opportunities for patients to take part in these studies if they want to. [00:23:20] Florence: Yeah. That's really incredible. Thank you for sharing that with us. I wanted to ask you a question now, Ali, because I think when we were talking about trials and projects like this, as Victoria said, we often think about kind of the high level impact, but also it's an opportunity to create connections as well between patients and families and, and I know that you, you had a patient's family reach out to you about advice as to-- about whether they should take part in a trial. Is that right? [00:23:47] Ali: Yeah. I think it was the wife of a guy up in Liverpool who had throat cancer, and, um, she must have done some really good research on the internet. I'd done various bits of publicity both for Southampton Uni and cancer research around the trial. So she obviously found me and then stalked me on Facebook , which was absolutely fine. [00:24:13] Ali: I didn't have a problem. So her husband was down to go on the trial, which is the next stage that Victoria had spoken about, and she just wanted to know, would I recommend it, would-- what was it like, that kind of thing. So I said to her, "I would absolutely recommend it, of course," and told her what my experience was. [00:24:35] Ali: I couldn't guarantee his would be the same, of course, because things might have moved on. But it was a really, it was a kind of a nice feeling that I could say to her, "Get him to have it done because it's got to be the best outcome." I think his stage was much further on than me. So yeah, it had to be the way as far as I could see for him. And as far as I know, he went on the trial. Which is great. [00:25:05] Florence: How, how did it feel to kind of make that human connection, maybe not something you were expecting to come out of a trial? [00:25:13] Ali: No, it was really, it was really nice. I am a bit of a, a fangirl for, for Lennard and Victoria and all the team at Southampton. [00:25:22] Ali: If anybody asks me about vaccines and cancer vaccines, I'm like, "Oh, yes." And you-- So yeah, I'm, I'm a bit of an evangelist. So to, to have somebody real- [00:25:33] Florence: Mm ... [00:25:34] Ali: ask me about that was great feeling. [00:25:37] Florence: I think that's a, a really great example of how research can have impact far beyond, uh, one individual. And I think another great example of this is also artificial intelligence or AI as a potentially transformative force in, in healthcare. [00:25:54] Florence: Lennard, when we come onto this topic, I wanted to hand over to you because I know that you've recently received funding for a project exploring AI, and how it could support cancer vaccine development in particular. Could you tell us a bit more about this project? [00:26:08] Lennard: Thanks very much, Florence. And I also want to add, I feel very proud about what Ali did just there, where she's able to bring through opportunity for other people, too, which is amazing. [00:26:19] Lennard: The NHS is there to not just do the technology of today, but also be one of the best healthcare systems in the world to bring through new technologies. And it's just really exciting about people wanting to help the NHS, advocating for new technologies to be tested, and actually that's what Genomics England i there to do, make sure the NHS gets new technology in there so that patients will get new treatments. [00:26:41] Lennard: I just wanna just reflect what Victoria noted In the NHS, in their Cancer Vaccine Launchpad, patients are getting in at three times the rate of other countries. [00:26:51] Ali: Mm-hmm. [00:26:52] Lennard: That's really special. And also she's increased coverage to, uh, did you say 60% of population? That's 42 million people have potential access to this. [00:27:01] Lennard: So that is huge, and I think it's really a passion project for so many people out there, PICT trials units, the research nurses and doctors, and also patients who make this all happen. So it is quite impressive. It is very impressive. Oh, yes, and AI. I probably should cover that too. Just beyond what's special about the NHS and Genomics England. [00:27:22] Lennard: Well, AI I think is changing everything. I went to a garden party, and actually everyone's talking about how they're using AI to make their lives simpler, make them do things that they've never been able to do before, get the information instantaneously there. And I think that there's technologies which come through every so often in our lifetimes, which changes how we think, how we communicate, and actually makes us better in many ways. [00:27:47] Lennard: And so the great opportunity here is what happens if we take that third strength now? So we've already said we're really good at vaccine research in the UK. The UK invented vaccines. We also are world leaders at genomics. We did the 100,000 Genome Project. What happens if we use this new technology now? [00:28:06] Lennard: And what's a problem that we can solve? Well, let's say we did a whole genome sequence on someone, which is what Genomics England does every day for the NHS. Well, that creates a lot of data. Um, I tried to do the calculations before we went online. It's about 100,000 photos. You know, when you take on your phone, that's a lot of data. [00:28:25] Florence: Wow. Yeah. [00:28:26] Lennard: And that's a miracle what's happening in the NHS and Genomic England, and we need to make a cancer vaccine out of that. And so you need to process that. So that's time-consuming. It could be automated. And so what AI could do now in future is that we could use the supercomputer we built in the UK. [00:28:43] Lennard: In fact, we are doing this already. We've built supercomputers in the UK, and we're going well beyond other tools out there and designing cancer vaccines. And the AI scientists which can do that can do it at weekends, at nights, and help design the drugs. And so what it does is it heralds a future where every patient can contribute into a model that's created in the UK, stored safely in our supercomputers. [00:29:07] Lennard: It can now be made into drugs, and the UK will start to make things again, which will hopefully change cancer care across the world. We can deliver that legacy whereby our three strongest strengths come together - vaccines, AI, and genomics. It then super powers the NHS and everything that Victoria's done in the Cancer Vaccine Launchpad, so many millions of people around the world can get access to trials. [00:29:31] Lennard: And people like Ali can also help hold up the NHS even further. So people once again look back to us and say, "If you want to get things done, come to the NHS because it provides world-class care for patients." And so that's a big initiative now. Use AI to make better drugs, safer drugs, more effective, more precise in the UK. And it's only possible because of everything that we've built here with our funders, ARIA, MRC, Cancer Research UK, people raising, raising money through cake bake sales to make this happen. [00:30:02] Lennard: So it's very exciting. [00:30:04] Florence: Yeah. I think AI can be a topic that people often have very strong opinions about. When it comes to AI in, in your line of work, are there any misconceptions you think people might have, or are there any benefits to using it that maybe people might not be aware of? [00:30:21] Lennard: Oh, that's a tricky question, isn't it? I think you're right. Any tool that comes through can be used for good things and, and things that people will question because maybe we don't want to cross those boundaries. And yet I think what we're doing here is really special because we want to - as long as your heart's in the right place - we want to give more people like Ali hope so that she knows that one day the drugs in the NHS will be much safer so you don't get all those side effects, much more effective, much more precise. [00:30:52] Lennard: And on top of that, people like Victoria will be able to bring even more trials in the UK which will change lives and change practices around the world through an amazing working launchpad. So I think that's the right use of AI, make people's lives better. I think there are other uses of AI which I probably scratch my head and say, "Well, should we be doing that?" [00:31:10] Lennard: And that's what I think it's really special that we do think about these and talk about these things here, and then bring the public with us because I know that people reach out, and Ali's been reached out in the past before, and I think we need to have this discussion here. Is AI right to develop cancer drugs using capabilities from Genomic England to go through the NHS Cancer Vaccine Launchpad? [00:31:31] Lennard: I say cautiously, yes, and we should do more of this. And I think the most important thing is there's a lot of people starting to use AI for benefit, and you know my views, Ali, and I don't know if they're right. Um, I'll be a bit cautious, but I do want to ask you, Ali, is this the right use of AI? Should this be what we develop? [00:31:50] Lennard: I don't know what you're going to say. [00:31:52] Ali: For me, I think it is. I do think AI is a bit if you put rubbish in, you get rubbish out. But if you- If you ask the right questions, if you give it data analysis and experts like you have set up the protocol in the first place and it makes everything faster and reliable, then it's got to be the right thing. [00:32:16] Ali: It gets used and abused for things, that isn't what AI should be doing, in my opinion. It should be used to do-- to help us, to supplement the work that we're doing, uh, and make it even faster than you're already making it. [00:32:38] Florence: Well, we've covered so much today from how vaccines work to the role of genomics, NHS trials, and of course, what all of this could lead to. So before we wrap up, I have two final questions for each of you. What do you think is the most important thing for listeners to understand and take away from personalised cancer vaccines? [00:33:01] Florence: And what are your hopes for the future? I think we'll start with you, Victoria, if that's all right. [00:33:08] Victoria: Yeah, absolutely. It's been a great conversation. Uh, there's so much to think about. I think when I think about what I'd like listeners to take away, I think it's that cancer vaccines, and particularly personalised cancer vaccines, really support and represent this paradigm shift that we're seeing towards a much more personalised, uh, treatment pathway. [00:33:27] Victoria: You know, like we've described, generating a cancer vaccine that has come from the patient's tumour, so the, the, the vaccine is, is designed to recognise mutations that are specific to that patient. It is such an incredible thing to be sort of witnessing and to see how that's developing through into sort of really changing patient care, and that's, you know, we've spoken about this so much, but that's been due to such incredible collaboration across scientific disciplines, across the NHS, pathologists. [00:33:58] Victoria: Everyone has come together to make all of this possible, and that's, that's an amazing thing to be a part of. In terms of my hopes for the future, well, I would like the Cancer Vaccine Launchpad to be open in every hospital across the UK to really sort of underpin that acceleration and to provide that opportunity for patients. [00:34:17] Victoria: You know, I'd just like to give a, a final shout-out to everybody who has been part of the Cancer Vaccine Launchpad from its very start, who's enabled this to happen and, you know, it's just been fantastic to see how this has, you know, supported patient choice for trials. And I guess if there's one tiny other thing, perhaps we could see how this, you know, this, what we've put together could be applied to other disease areas as well. [00:34:39] Victoria: But yeah, that, that would be my hope for the future, is it's open everywhere one day. [00:34:43] Florence: And Ali, I'll come over to you next. [00:34:45] Ali: I think what I'd say to any patient that was asked to go on a trial is, is just go for it. [00:35:02] Ali: And you know, Victoria, Lennard, all the rest of the team, you know, you are not doing jobs. You're leaving a legacy in my view. That's such an important thing. So yeah, if you're offered a trial, get on it. And my hope for the future is that everybody can have kinder, gentler treatments. The radiologists and chemo nurses I came across were lovely, lovely people. [00:35:31] Ali: But yes, I'd like to see them out of work and doing other things within the NHS because they don't need to do that work anymore. That, that's my dream. [00:35:40] Florence: Mm. And Lennard, any, any final thoughts? [00:35:44] Lennard: Thanks, Ali. I mean, your words gave me goosebumps about the amazing stuff that the whole community's doing for cancer vaccines, AI and genomic research. [00:35:51] Lennard: It's so powerful. Um, okay. What's the final thing? I think it's hope. Look, the country's in a new place now. You've got brilliant scientists running clinical trials, like the Cancer Vaccine Launchpad, which is reaching out to every single hospital. You've got patients who are building up the NHS again to deliver future care, and scientists using AI and genomics to make cancer vaccines. [00:36:11] Lennard: That is a good reason to be hopeful. When lots of things are going in other places of the world, great things are happening in the UK. [00:36:20] Florence: This has been such a brilliant conversation. [00:36:25] Florence: A huge, huge thank you to our guests today, Dr. Victoria Goss, Professor Lennard Lee, and Ali Richards, for joining me in our brilliant discussion about cancer vaccines. [00:36:50] Victoria: Thank you so much for having me. [00:36:55] Ali: Thank you, as always. I've learnt a lot. [00:37:00] Lennard: Thank you very much, Florence, too, from me. [00:37:10] Florence: If listeners have enjoyed this episode and you'd like to hear more, please subscribe to Behind the Genes on your favourite podcast app. [00:37:16] Florence: I've been your host, Florence Cornish, and Behind the Genes is produced by Deanna Barac, Sharon Jones, Sophie McLachlan, and Patrick Wallace at Bespoken Media. Thank you for listening.
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3vu —— 以上為 Firstory Podcast 廣告 —— 加入會員，支持節目： https://masterstrangehistory.firstory.io/join留言告訴我你對這一集的想法： https://open.firstory.me/user/ck7jykyq8abn60873daiihxpk/comments【奇異碩士】在空中陪伴你的週日早晨！ 每週日早上八點到九點，寶島聯播網 - 北部寶島新聲FM98.5、中部大千電台99.1，和你一起討論歷史和時事的話題！ https://www.baodaoradio.com.tw/ 【奇異碩士】EP. 073 服務性社團已經是歷史名詞了嗎？ 回覆留言：Z世代整頓職場？還是來亂？沒有什麼都要的啦！
In this listener Q&A episode, Dr. Susan Hudson from Texas Fertility Center and Dr. Carrie Bedient from Fertility Center of Las Vegas breakdown the real information patients need to know. We're tackling some of your biggest questions about fertility testing—from BV, HPV, AMH, and sperm counts to PGT-A, failed FETs, tubal issues, and when it may be time to consider IVF. We break down what the evidence actually tells us, which tests may be worth considering, and when additional testing is unlikely to change the next step. Plus, we discuss fertility testing in early pregnancy and share practical guidance for navigating the often-confusing world of fertility workups. Tune in for real answers from real patients going through their fertility journeys!
Women who have missed a cervical screening appointment in England are to be offered HPV self-testing kits by the NHS. Over the next year, nearly four million women will receive invites on the NHS App or via text message, email or letter to order a free kit to use at home. The aim is to encourage more women to complete their potentially lifesaving screening to detect HPV, which can increase the risk of cervical cancer. Figures show that around a third of women who are eligible for cervical cancer screening have not taken up the offer recently. Dr Sue Mann, National Clinical Director for Women's Health in England and a consultant in Sexual and Reproductive Health, joins Nuala McGovern to discuss.Chef Sally Abe, who owns the restaurant The Pem, and Kayla Lawrie, a producer with social media food influencers TopJaw, have launched a map of women-owned hospitality businesses. What began with 350 restaurants, pubs, cafés and bakeries has now grown to more than 1,000 venues across the UK. They explain to Nuala what they hope to achieve.Around 7,500 women are diagnosed with ovarian cancer every year, with the majority aged over 50. But around 120 of those women are between 15 and 24. Enlli Thompson was just 19 when a growth was found on one of her ovaries. Since then, she's undergone chemotherapy, egg freezing, a hysterectomy and medically induced menopause. Enlli joins Nuala, alongside GP Charlotte Badescu, who was also diagnosed with ovarian cancer in 2021 when she was 31.Stephanie Brown from the University of Hull has spent the past year as Woman's Hour's researcher in residence on the scheme that Radio 4 runs with the Arts and Humanities Research Council. She studies the history of crime and, as part of our summer series exploring some of the latest research into women's lives past and present, she shares new findings about the punishment of women in medieval England.Is your wardrobe a clutter-free haven of beautifully coordinated outfits? Or is it more a chaotic jumble of jumpers, jeans and everything in between? Could an app be the answer? Some apps allow users to catalogue what they own, visualise outfits and experiment with their style. Nuala is joined by Nicole Glennon, Deputy Editor of the Irish Examiner Weekend magazine, and Dion Terrelonge, fashion psychologist and practitioner.Presenter: Nuala McGovern Producer: Dianne McGregor
Can preterm birth be prevented? Historically the answer has been no, and the numbers back that up. In 2006 the U.S. preterm birth rate was about 12 percent. In 2024 it was 10.4 percent. Medicine has gotten dramatically better at keeping premature babies alive, but almost no better at keeping pregnancies from ending early. In this episode, Kristin and Dr. Abdelhak make the case that the answer is yes, preterm birth can be prevented far more often than it is now, and that the field has been looking in the wrong place. Preterm birth is not one condition. It is a grab bag: placental abruption, systemic infection like appendicitis or pyelonephritis, uterine overdistension from twins, triplets, or polyhydramnios, trauma, severe hypertension, stimulant and cocaine use. Every one of those causes announces itself. The woman with triplets is obviously carrying triplets. The woman with an abruption is bleeding and in pain. So what about the woman with none of that, doing everything right, who shows up at 30 weeks contracting and three centimeters dilated? For forty years the answer was "subclinical infection," a diagnosis Dr. Abdelhak takes apart in this episode. If it is subclinical, why is preterm labor the only clinical thing it ever does? Why does an appendicitis start with pain and fever and end in labor, while this mystery infection skips straight to the last step? And after four decades of amniocentesis studies cataloguing cytokines, interleukins, and prostaglandins, where is the treatment? There isn't one, because researchers found exactly what they went looking for. His answer is mechanical, not microbial. The cervix is a timekeeper on the pregnancy. Conventional teaching says contractions open the cervix. He argues it runs the other way: the cervix quietly gives way over weeks, and when it opens far enough, labor starts. That is why he says he is almost never surprised by a preterm labor. He was already watching the cervix shorten. Also covered: why previous preterm birth is the single strongest risk factor (it is the same cervix), why cone biopsy raises risk more than LEEP does, what funneling on ultrasound actually tells you, the difference between classic cervical insufficiency and the milder version that still lets you reach the third trimester, and why a three-hour precipitous labor at 38 weeks may be the same finding wearing a friendlier face. The practical takeaway: serial cervical length measurement for anyone with a red flag, first-time moms included, and cerclage when the cervix starts to open. Screening plus treatment, not a pill for an infection nobody can find. Plus: why the president and Taylor Swift would get their cervix measured every single week, and what that tells you about the standard of care the rest of us are offered. Topics covered, in order Why this topic is worth repeating, and why the framing here is not the conventional one The better question: preventing preterm birth, not preterm labor Fifty years, the March of Dimes, and a rate that has barely moved What we did get better at: neonatal survival and outcomes, not prevention Preterm birth as a grab bag, not a single disease Placental abruption Systemic infection: appendicitis, pyelonephritis, sepsis, severe pneumonia, COVID The subclinical infection theory, and the case against it Why the amniocentesis and cytokine studies found what they set out to find Uterine overdistension: twins, triplets, polyhydramnios Trauma, decidual hemorrhage Severe hypertension, pulsatile flow, and abruption risk before 20 weeks Cocaine, methamphetamine, smoking The patient nobody can explain, and what is actually going on The core claim: dilation causes the contractions, not the other way around Why Dr. Abdelhak is rarely surprised by a preterm labor Mild cervical insufficiency, and "dreamlike" cervical insufficiency at 38 weeks Why previous preterm birth is the number one risk factor LEEP versus cone biopsy, and why cone matters more Normal variation in cervical length, and the big nose analogy Length is not everything: bulk, thickness, and how the cervix feels Funneling on ultrasound as a warning sign The proposal: serial cervical length screening plus cerclage Why the numbers are U.S. numbers, and why international rates are not trustworthy The VIP standard of care, and who actually gets weekly scans Key takeaways Preterm birth is not one condition. Abruption, systemic infection, overdistension, trauma, and severe hypertension each have their own mechanism, and each is usually obvious on arrival. "Subclinical infection" is not a diagnosis, it is a placeholder. Forty years in, it has produced no treatment and no measurable drop in the preterm birth rate. The cervix is the timekeeper. When it is weak, it opens slowly over weeks, and labor follows the opening rather than causing it. Previous preterm birth predicts the next one because it is the same cervix. You cannot order a new one. Cone biopsy raises preterm birth risk more than LEEP, because more cervix is removed. Length is a clue, not a verdict. Plenty of women have naturally short cervixes and carry to term. Funneling, bulk, and change over time matter as much as a single number. The intervention that would move the needle already exists. Serial cervical length measurement in anyone with a risk factor, and cerclage when it starts to open. Screening and treatment, not a mystery pill. Terms mentioned Placental abruption — the placenta separating from the uterine wall before delivery. Pyelonephritis — kidney infection. Polyhydramnios — too much amniotic fluid. Uterine overdistension — the uterus stretched beyond its comfortable capacity, as with twins or triplets. Cervical insufficiency — a cervix that opens without labor. Funneling — the cervix opening from the inside out, visible on ultrasound before any external change. Cerclage — a stitch placed to reinforce the cervix. LEEP and cone biopsy — procedures removing cervical tissue after abnormal Pap or HPV findings. Precipitous labor — a very fast labor, often under three hours. Memorable quotes: "I am telling you what happened was the three centimeters dilated caused the contractions." "If it's subclinical, why doesn't it stay that way?" "The cervix is a mechanical timekeeper on the pregnancy." Got something you want to share or ask? Keep it coming. We love hearing from you. Email us or send a voice memo, and you might just hear it on the next episode. Don't forget to like, comment, and subscribe your questions could be featured in our next episode. For additional resources and information, be sure to visit our website at Maternal Resources: https://www.maternalresources.org/ You can also connect with us on our social channels to stay up-to-date with the latest news, episodes, and community engagement: YouTube: youtube.com/maternalresources Instagram: @maternalresources Facebook: facebook.com/IntegrativeOB TikTok: NatureBack Doc on TikTok Grab Our Book: The NatureBack Method for Birth—your guide to an empowered pregnancy and delivery. Shop now at naturebackbook.myshopify.com
FREEDOM - HEALTH - HAPPINESSFor the full episodes please subscribe to either:The paid Spotify subscription here: https://creators.spotify.com/pod/show/docmalik/subscribe The paid Substack subscription here: https://docmalik.substack.com/subscribeThank you to all the new subscribers for your lovely messages and reviews! And a big thanks to my existing subscribers for sticking with me and supporting the show! ABOUT THIS CONVERSATION: I talk to Ignored Science about the HPV vaccine and more. See my substack for more details. DocLinks Substack https://docmalik.substack.com/p/502-ignored-science-hpv-vaccines-afb?MY CONSULTATION SERVICEIn a world of rushed consultations and endless referrals, I offer you something rare: time, context, and clear guidance.I can help you:• Understand your diagnosis in plain English• Simplify treatment plans and medical jargon• Prepare for surgery and optimise recovery• Improve chronic illness through lifestyle and mindset• Explore holistic approaches alongside conventional care• Ask better questions and get unbiased guidance• Obtain an independent second opinionReady to Take Control?Book here today https://docmalik.com/consultations/ Check out my AFFILIATE LINKS - visit my website https://docmalik.com/affiliates/ for more detailsSeagreenUse the code DOCMALIKhttps://seagreens.shop/go/docmalik/Heracles Wellness SaunaUse the code DOCMALIK3 at checkout to get 3% off all productshttps://heracleswellness.co.ukHunter & Gather Foodshttps://hunterandgatherfoods.com/?ref=DOCHG BUY HERE TODAYUse DOCHG to get 10% OFF your purchaseNudum SkincareUse my code DocMalik10 at checkout to get 10% off your order.https://www.nudumskincare.co.uk/Greenscents Laundry LiquidUse code GSAHMADMALIK when ordering to receive a discount.https://greenscents.co.uk?bg_ref=pmW7ecKqjqIMPORTANT NOTICEIf you value my podcasts, please support the show by making a one-off donationhttps://www.buymeacoffee.com/docmalik
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3tt —— 以上為 Firstory Podcast 廣告 —— [本集重點]✰ 來賓 Lukas @lukaz7777☛ 有泰國夢的人聽這集！從外派到 Local hire，在曼谷生活容易嗎？☛ 工作不是全部，工作只是生活的一部份～泰國人更在意工作與生活的平衡☛ 如果失業，空窗期不能太長？小心簽證出問題☛ 泰國生活觀察：宗教文化、社交模式與多元包容性⊗ 未滿18歲請勿收聽 ⊗—————— ฅ՞• •՞ฅ ——————✰ 訂閱 & 分享給就是對我們最好的支持 ☛ 官網：https://dt-talk.com/☛ 射粉電子報：https://lihi1.me/AKkAT☛ 集體蕭貪之好康射給你【射後團購群】：https://lihi2.com/iyzOR （通關密碼：1069）✰✰ 歡迎乾爹乾媽來包養 ☛ 廠商合作請來信：dttalk@dt-talk.com ✰✰✰ 聊得喉嚨好乾，心有餘力的話就請我們吃川貝枇杷膏吧！☛ 捐款連結：https://dt-talk.com/support (點選單次付費即可捐款） Powered by Firstory Hosting
If you are on hormone therapy and still dealing with dryness, painful sex, or leaking when you laugh, this episode is for you. Estrogen and progesterone do a lot of good work. They protect your bones, your heart, and your brain. But systemic hormones do not reach everything. There is a whole area of your body they mostly skip, and that is where a lot of women are still struggling in silence. Dr. Anna Cabeca is a triple board certified OBGYN who delivered thousands of babies before she started asking why so many of her patients were not getting better. In this episode she explains why vaginal estrogen alone often is not enough either, and what she uses instead. She also explains the vaginal microbiome. Your standard panel looks for infections. It does not check whether your protective bacteria are still there. And as we age, that protection thins out, which raises the risk of recurring infections, bladder problems, and even HPV. We talk about topical DHEA and testosterone, why they reach the deeper tissue that estrogen cannot, and how she watched patients scheduled for incontinence surgery improve enough that they no longer needed it. Menopause is mandatory. Suffering is not. Want more practical health tips? Join my newsletter! https://freechapter.lpages.co/newsletter-opt-in/ "Fine" isn't the same as well. Stop waiting to collapse before someone listens. Build your case: https://freechapter.lpages.co/how-to-build-a-case-for-yourself/ Check us out on social media: https://www.instagram.com/drefratlamandre https://www.facebook.com/drefratlamandre https://www.tiktok.com/@drefratlamandre #functionalmedicine #drefratlamandre #medicaldisruptor #NPwithaPHD #nursepractitioner #medicalgaslighting Chapters 0:00 - Introduction 3:13 - From 2-3 Surgeries a Week to 2-3 a Year 11:44 - The Vaginal Microbiome Your Annual Exam Misses 17:36 - A Preventable Stage 4 Cervical Cancer Story 24:27 - Topical Hormones for Dryness and Incontinence 39:14 - Pushback and Rapid Fire Questions Guest Links: IG: https://www.instagram.com/thegirlfrienddoctor YT: https://www.youtube.com/thegirlfrienddoctor Website: https://dranna.com Learn more about your ad choices. Visit megaphone.fm/adchoices
What does cancer prevention look like through the eyes of a 13-year-old?In this special episode of the Cervivor Podcast, host Joslyn Chaiprasert-Paguio sits down with her daughter, Samantha, to talk about growing up alongside her mom's cervical cancer journey, her decision to get the HPV vaccine, and why she believes young people should be part of conversations about their health.Plus, Cervivor Podcast Producer and International Correspondent Jagruti Dave shares recent research examining HPV vaccination rates and cervical cancer trends across the U.S.Tune in for a powerful mother-daughter conversation about prevention, education, and the impact cervical cancer can have on the entire family.
Questo episodio fa parte della serie “Di scienza e altre storie”: storie di uomini e donne i cui destini, talvolta per caso, si sono intrecciati con la scienza.Nel 1951 Henrietta Lacks morì a soli 31 anni per un aggressivo tumore al collo dell'utero. Una parte di lei, tuttavia, non ha mai smesso di vivere.Prelevate senza che ne fosse informata, le sue cellule continuarono a moltiplicarsi in laboratorio, diventando la prima linea cellulare umana capace di proliferare potenzialmente all'infinito. Conosciute come cellule HeLa, contribuirono alla ricerca sul vaccino contro la poliomielite, sul cancro, sui virus, sulla genetica e su numerosi farmaci.Questa non è soltanto la storia di una straordinaria scoperta scientifica. È anche una vicenda di silenzi, discriminazione, consenso negato e memoria restituita.Una storia nella quale il progresso della medicina incontra una domanda ancora attuale: può una grande scoperta cancellare la persona da cui tutto è cominciato?
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3um —— 以上為 Firstory Podcast 廣告 —— 吉時保： https://fstry.pse.is/9mtbse 免指定車牌、車型，用車前1小時投保，手機投保5分鐘新安東京海上產險｜0800-369-168｜104台北市中山區南京東路三段130號8-13樓 —— 以上為 Firstory Podcast 廣告 —— 加入會員，支持節目： https://xxymovie.firstory.io/join留言告訴我你對這一集的想法： https://open.firstory.me/user/ck2ymcbpa2cpi0869qq23bkji/comments【看什麼電影】《終戰那一天》The Day The War Ended 重回1945年08月15日，我們既是戰敗也是戰勝的那一天 feat. 導演 盧慈穎
What does it look like to build public health programs around what a community actually needs? In this episode of Plugged into Public Health, Lauren talks with Zuli Garcia, founder and president of Knock and Drop Iowa. The organization began in Zuli's garage during the COVID-19 pandemic as a culturally specific Latino food pantry and has since grown into a multicultural organization serving hundreds of Iowa households each week. Zuli shares why culturally appropriate food matters, how Knock and Drop Iowa grew from an emergency response into a nonprofit, and how food rescue and partnerships with local organizations help the pantry serve families across the Des Moines area. The conversation also explores Knock and Drop Iowa's expansion into health education and vaccine access. Zuli discusses how her own experience with cervical cancer influenced her work around HPV education, screening, vaccination, and patient advocacy, and why making health information convenient, understandable, and culturally responsive is critical. Throughout the episode, Zuli explains how Knock and Drop Iowa has built trust by listening to communities, partnering with trusted local leaders, and bringing resources into existing events and spaces rather than expecting people to come to them. It's a conversation about food insecurity, access to care, cultural responsiveness, community trust, and what it means to truly meet people where they are. Learn more about Knock and Drop Iowa: To learn more, get involved, request programming in your community, or support the organization: Email Zuli at zuli@knockndropiowa.org Call or text 515-330-6077 Visit the Knock and Drop Iowa website for information about volunteering and ways to donate. A transcript of this episode is available at https://www.public-health.uiowa.edu/news-items/plugged-in-to-public-health-meeting-communities-where-they-are-with-zuli-garcia-and-knock-and-drop-iowa/ Have a question for our podcast crew or an idea for an episode? You can email them at CPH-GradAmbassador@uiowa.edu You can also support Plugged in to Public Health by sharing this episode and others with your friends, colleagues, and social networks. #publichealth #communityhealth #foodpantry #latino #culturalimportance #healthscreening #foodinsecurity #nonprofit #CEO #iowacity
Many women are told their labs are "normal," or they aren't offered certain tests that would provide additional information, including nutrient levels. But these levels matter when it comes to clearing HPV and preventing HPV-related cancer, as well as other health issues. In this episode, I explain why getting "normal" lab results doesn't necessarily mean everything is fine. And 6 tests I feel should be ordered for women who are testing positive for HPV. I also explain that the reference ranges on lab reports are not necessarily "optimal" levels, and what levels you do want. Standard reference ranges often aren't good enough if you want to understand what is really going on in your body — including why you might still be testing positive for high-risk HPV or dealing with other unresolved health issues. I'm here to help you! LINKS FROM THE EPISODE: Get The HPV Support Supplement Bundle: https://doctordoni.com/product/hpv-support-bundle/ Sign up for Dr. Doni's 5-Day HPV Workshop: https://doctordoni.com/HPV-workshop/ Schedule A Chat With Dr. Doni: https://intakeq.com/new/hhsnib/vuaovx Read the full episode notes and find more information: https://doctordoni.com/blog/podcasts/ MORE RESOURCES FROM DR. DONI: Quick links to social media, free guides and programs, and more: https://doctordoni.com/links Disclosure: Some of the links in this post are product links and affiliate links and if you go through them to make a purchase I will earn a commission at no cost to you. Keep in mind that I link these companies and their products because of their quality and not because of the commission I receive from your purchases. The decision is yours, and whether or not you decide to buy something is completely up to you.
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3s7 —— 以上為 Firstory Podcast 廣告 —— 「站穩了，我就能回家｜溫叨一條街」計畫透過中途住宿、心理諮商、就業培力與家庭支持，陪伴藥癮復元者重新適應生活、穩定就業，並逐步走回家庭與社會。
What if safer sex didn't have to be rooted in fear? In this episode of Please Me!, Eve Hall and Robert Johnson explore how modern sexual health tools are changing the way we think about STIs, HPV, HIV prevention, STI testing, and sexual freedom. Robert shares practical insights on HPV vaccination, PrEP, DoxyPEP, routine STI screening, three-site testing, and communicating openly with sexual partners. They also discuss how advances in sexual health have made it possible to approach intimacy with more knowledge, confidence, and eradicate shame. In This Episode: HPV vaccination and sexual health prevention HIV prevention and PrEP DoxyPEP for STI prevention Why routine STI testing matters Three-site testing for gonorrhea and chlamydia HPV, herpes, and other common STIs How to talk to partners about STI status and testing Sharing test results and informed consent Sexual health breakthroughs from hepatitis vaccines to modern HIV prevention Medications that may support sexual function, blood flow, lubrication, and sensitivity Building a healthier, more confident approach to sexual longevity Connect with Robert Robert Johnson (Shameless Care)Website: shamelesscare.com Podcast: Sex Is Good Podcast Connect with Eve: Reach out for questions, partnerships, retreats, speaking engagements, or collaborations. Boudoir posters of Eve are also available by request, with donations starting at $150. Only five signed copies of each image will be available. Contact - Please Me! Explore the Sexual Longevity Protocol: https://pleaseme.online/the-sexual-longevity-protocol/ A science-based course by Eve, a Sexual Health Physical Therapist to help you improve sexual function, confidence, and pleasure for life. Lifetime access for just $47. Affiliate Deals & Partners:• Join the Please Me! Media Newsletter:(1) Eve Hall | Substack • Become a Patreon of Please Me! Media: https://www.patreon.com/PleaseMePodcast • Parlor Games Bioidentical Hormones: Parlor Games | Shop • Shameless Care: Sex Positive Healthcare: (Code: PLEASEME): STD Testing, STD Prevention, and ED Meds - Shameless Care • Become a member for free monthly webinars (Code: PLEASEME): SDC Swingers Lifestyle: Seek, Discover, Connect | SDC.com • Lady Pump: Lady Pump – TheLadyPump • Penis Pump: Auto GRO Pump - Dr. Joel Kaplan • Cakes Nipple Covers: (Code: CAKES-PLEASEME 10% off) Sticky Starter Pack | Our Best Sticky Offer, $33 Savings – CAKES body Thank you for supporting my affiliate partners. Every purchase helps support the Please Me! Media mission. The Mom Economy Anthology Book is A USA Bestseller: I'm proud to be part of this collaboration. My chapter is deeply personal and shares what I most want my daughters—and the next generation of women—to know. The Kindle edition is available now for $1.99, with the paperback available as this episode drops. Purchase the Kindle version here: https://a.co/d/01HpPGN2 The Mom Economy Magazine: Check out my featured article of this magazine for only $2.99 here: The Mom Economy Magazine | July 2026 Edition | She Rises Studios Be a Guest On Please Me! A Sexuality Podcast: :Be a Guest on Please Me! PodcastShare your story or expertise on relationships, sexual health, and personal growth
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3vu —— 以上為 Firstory Podcast 廣告 —— 加入會員，支持節目： https://masterstrangehistory.firstory.io/join留言告訴我你對這一集的想法： https://open.firstory.me/user/ck7jykyq8abn60873daiihxpk/comments【奇異碩士】在空中陪伴你的週日早晨！ 每週日早上八點到九點，寶島聯播網 - 北部寶島新聲FM98.5、中部大千電台99.1，和你一起討論歷史和時事的話題！ https://www.baodaoradio.com.tw/ 【奇異碩士】EP. 072 《再見1987》導演吳宗叡來啦！ 原來拍這部劇是為了達成粉紅泡泡的成就？ 一段跨越臺灣、日本、韓國歷史的動人故事！
跟另一伴攜手走下去前，不只是甜言蜜語、浪漫送禮，這件事做好準備更重要！預防 HPV 是對彼此「愛情」最基本的尊重和承諾。別讓對健康的傷害變成愛情的阻礙，為彼此主動做好HPV預防才能說是「真愛」。立即諮詢醫師，展現你對愛的承諾。男女1+1 主動防禦HPV(人類乳突病毒) https://fstry.pse.is/9ep3sd —— 以上為 Firstory Podcast 廣告 —— 用CATCHPLAY+隨時掌握最新脈動！一站收錄TVBS、東森、BBC、NHK等國內外主流新聞直播。支援手機、電腦、電視播放。限時訂閱頻道加影劇3個月599元，輸入優惠碼【100】再折100元！ https://fstry.pse.is/9k7b2k —— 以上為 KKBOX 與 Firstory Podcast 廣告 —— 2026 八月活動消息 !! =================================================== 《#54321歡迎收聽怪獸訓練電台》新書分享會來啦 陪伴式訓練科普Podcast / YT頻道「怪獸訓練電台」移地開播！ 何立安老師和Josh大叔都會出現喔！
About this episode: This summer, Merck & Co. settled more than 200 lawsuits alleging that the company's HPV vaccine, Gardasil, caused cases of autoimmune conditions and fertility issues in young women. But that $50 million settlement is not an admission of fault on the part of the company or the vaccine. In this episode: Vaccine law expert Dorit Reiss details the lawsuits, including why evidence isn't stacking up for plaintiffs and how headlines about the dollar amount can misconstrue the facts of the case. Guest: Dorit Reiss, PhD, is an expert on vaccine policy and a professor of law at UC San Francisco. Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: Merck to Settle Bulk of Gardasil Suits for About $50 Million—Bloomberg Kennedy played key role in Gardasil vaccine case against Merck—Reuters What VAERS Is (And Isn't)—Johns Hopkins Bloomberg School of Public Health The HPV Vaccine, 20 Years Later—Public Health On Call (August 2026) Vaccines 101: The Vaccine Injury Compensation Program—Public Health On Call (February 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @PublicHealthPod on Bluesky @PublicHealthPod on Instagram @JohnsHopkinsSPH on Facebook @PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
Send us Fan MailA “full panel” STI test sounds like peace of mind until you learn what it often leaves out. We sit down with Robert Johnson, founder of Shameless Care, to unpack the testing blind spots that can quietly miss infections, especially when oral exposure is part of your sex life. His turning point is painfully relatable: a partner flags possible gonorrhea, he feels totally fine, and he is staring at a negative result from the week before. The catch? No throat swab, no real clarity.We get specific about how STI testing actually works in the real world: why blood and urine alone may not be enough, why most STIs are asymptomatic, and why “full panel” is not a standardized button your doctor can click. Robert also explains how shame changes what people say in the exam room and how that can snowball into incomplete care. If you have ever walked out of a clinic thinking you were tested for “everything,” this conversation gives you better questions to ask and a clearer way to read your results.Then we zoom out into prevention and modern sexual health tools. We talk PrEP as an HIV prevention breakthrough, U equals U and what it means for transmission, and DoxyPEP as a promising option that also raises real concerns about antibiotic resistance. We also highlight vaccines like HPV and hepatitis B as practical, cancer-preventing steps that too many adults still miss.If you want smarter, shame-free sexual health information that you can actually use, listen now, share this with someone who dates, and leave a review so more people find it. What did your last STI test truly include?https://shamelesscare.com/https://youtu.be/e36gU87R-sU?si=dVsNUK8G9HcQSf7QPodcast: Sex Is Good https://www.buzzsprout.com/2505799 Support the show
Broadcast from KSQD, Santa Cruz on 8-06-2026: >ul> An emailer with persistent nine-month nerve damage in her right leg after a hysterectomy asks whether peptides could help. Dr. Dawn attributes the injury to lithotomy positioning during surgery, then reviews the main nerve-regeneration candidates in the FDA peptide review pipeline: BPC-157 (Body Protection Compound, strong rat data on sciatic nerve recovery with thicker myelin sheaths), intracellular sigma peptide (targets glial scar CSPGs blocking CNS regrowth), C3 peptide 156-181, GHK-Cu (copper peptide, upregulates nerve growth factor and neurotrophin-3), self-assembling hydrogel scaffolds for bridging nerve gaps, ARA-290/cibinetide (an erythropoietin fragment with early small fiber neuropathy trial data), and Semax (used internationally for stroke rehab). She adds standard functional-medicine adjuncts: alpha-lipoic acid, methylated B12, and methylfolate at high doses for six months. An emailer asks about safe features when buying an infrared sauna. Dr. Dawn covers three concerns: EMF exposure (look for shielded/grounded heaters testing under 1 milligauss at seat level, avoid unshielded Wi-Fi and Bluetooth panels); VOC off-gassing (avoid plywood, particle board, and MDF because of formaldehyde and benzene release, and avoid Western red cedar and pine because of high terpene emissions and instead choose poplar, basswood, or eucalyptus); and avoid built-in oxygen ionizers, which produce ozone as a coronal-discharge byproduct that irritates airways and generates secondary oxygenated VOCs. Dr. Dawn covers the surprisingly long list of medications that raise estrogen in middle-aged men—including nearly all antidepressants and antiepileptics, statins, NSAIDs (specifically naproxen and indomethacin but not ibuprofen), most blood pressure medications, PPIs, H2 blockers, Parkinson's drugs, antihistamines, and muscle relaxants. She recommends annual monitoring of the estrogen-to-testosterone ratio and offers rebalancing options: topical chrysin (blocks aromatization), indole-3-carbinol, calcium D-glucarate (blocks enterohepatic estrogen recirculation), soy (competitive receptor inhibition), and grape skin extract. The first mRNA-based flu vaccine was approved this week for adults 50 and over. Beyond the 27% improvement in seasonal efficacy over conventional shots, the strategic advantage is manufacturing speed. This will be critical when or if bird flu mutates to respiratory human transmission. Since mRNA vaccine can be reprogrammed from a new viral sequence in weeks versus the three-to-four-month growth cycle for conventional flu vaccines, rapid response can save lives. But mRNA vaccine side effects include more injection-site pain and fatigue - more like a tetanus shot than a traditional flu shot.. A Spanish prospective study of chemicals affected puberty in the young studied 500 girls followed from ages 7-10 and again at 14-16 used urine chemical measurements as objective exposure markers rather than food diaries. Ethylenethiourea, a metabolite of dithiocarbamate fungicides used heavily on strawberriess,was associated with earlier menarche, while a chlorpyrifos metabolite was associated with delayed menarche. this latter effect was more pronounced in overweight girls whose fat tissue concentrated the compound. Dr. Dawn recommends organic strawberries and keeping children away from fumigated fields. University of Pennsylvania School of Dental Medicine researchers developed a chewing gum from lablab beans containing the natural antiviral protein FRIL, which reduced oral HPV by up to 93% in samples from head and neck squamous cell carcinoma patients. The gum also suppressed Fusobacterium nucleatum and Porphyromonas gingivalis, oral bacteria that promote cancer recurrence. Michigan State University's Hamburger lab studying delphinium (larkspur) alkaloids joined forces with Tomáš Pluskal's Czech Academy of Sciences lab studying wolfsbane (monkshood) after meeting at a Barcelona conference. Together they mapped the biosynthetic assembly line for aconite—an alkaloid with valuable applications against malaria, pain, cancer, and agricultural pests but impossibly slow to extract from source plants—and cloned the pathway into tobacco, which grows aggressively and produces large quantities of the compound. An emailer named in the message asks about an incidentally-discovered enlarged aorta on CT. Dr. Dawn notes it officially becomes an aneurysm at 4 cm (annual monitoring) or 5 cm (six-month monitoring), with smoking cessation critical since tobacco directly weakens the aortic wall. She describes the "zipper of fire" back pain of dissection versus catastrophic rupture, and notes Medicare covers a one-time screening ultrasound for ever-smokers over 65.
About this episode: In the two decades since the HPV vaccine was approved, women's risk of developing cervical cancer has dropped by 80% for those vaccinated before age 16 and 66% in those vaccinated after age 16. It has also lowered the risk of other HPV-related cancers in men. In this episode: Journalist Liz Szabo recounts the incredible successes of this intervention in preventing cancer and discusses the existing misinformation surrounding the vaccine, still considered by some to be too "new." Guest: Liz Szabo, MA, is an investigative health reporter with CIDRAP News. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: 20 Years of HPV Vaccine Success—CIDRAP News Do I Need an HPV Vaccine?—Johns Hopkins Bloomberg School of Public Health Preventing Cancer: The Far-Reaching Impact of Vaccines—International Vaccine Access Center Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @PublicHealthPod on Bluesky @PublicHealthPod on Instagram @JohnsHopkinsSPH on Facebook @PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.
This week's episode was supposed to be a deeper dive into perimenopause, but as I started talking, the conversation went somewhere completely different. And honestly, I think it went exactly where it needed to go.I open up about some very personal parts of my health journey, including living with HPV, abnormal pap smears, precancerous cervical cells, and a recent conversation with my doctor about potentially having a partial hysterectomy. That conversation brought up so many questions for me about what happens to our bodies as we age and the parts of womanhood we don't talk about nearly enough.I also share what I've noticed changing in my 40s when it comes to sex, libido, vaginal health, and how those changes have affected the way I see myself as a woman. We talk about vaginal estrogen, recurrent UTIs during perimenopause, my recent experience with an infection I initially ignored, and why listening to our bodies and advocating for our health matters so much.In this episode, we discuss:Living with HPV and my history of abnormal pap smearsWhy my doctor brought up a partial hysterectomySex, libido, vaginal dryness, and intimacy in your 40sVaginal estrogen and vaginal health during perimenopauseMy recent UTI experience and why I wish I had acted soonerLearning to listen to your body and advocate for yourselfIf you've been experiencing changes in your body that you don't understand, putting off an appointment, or simply wondering why no one ever taught us about some of these things, I hope this conversation encourages you to ask questions, listen to your gut, and take your health seriously.Our bodies are such a gift, and sometimes, watching them change can be harder and more emotional than we expect.Here's to asking more questions and learning as we go. ❤️WANT TO JOIN A COMMUNITY THAT UNDERSTANDS THIS? Sign up for my next 30 Day Challenge: CORE, PELVIC FLOOR + HORMONE STRENGTH, starting August 31, 2026…go to heidipowell.net/reset or click HERE.Here are the key moments from the episode:00:00 Why I'm Going Deeper Into My Perimenopause Journey03:19 What I've Learned From Living Through Perimenopause at 4405:55 HPV, Cervical Cancer Risk & What Women Need to Know08:43 Why I Refuse to Skip My Annual Pap Smear11:42 The Partial Hysterectomy Decision I'm Now Facing14:28 Sex, Libido & Vaginal Changes During Perimenopause17:15 The Emotional Reality of Watching Your Body Age20:20 The Bladder Symptoms I Mistook for Something Else23:28 My UTI Got Worse: When I Finally Went to Urgent Care25:08 Why UTIs Can Become a Bigger Problem During Perimenopause27:28 Vaginal Health Signs Women Shouldn't Ignore28:24 The Health Checks I Want Every Woman to Stop Putting OffConnect with Heidi:Website: https://heidipowell.net/Email: podcast@heidipowell.netInstagram: @realheidipowellFacebook: Heidi PowellYouTube: @RealHeidiPowellJoin Heidi's next Hormone Reset Challenge: heidipowell.net/resetTrain with Heidi on her Show Up App: https://www.showupfit.app/
© 2020-2026 Ivy Podcast Discovery LLC
